Dec 01, 2022 5:03pm EST Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Nov 10, 2022 4:05pm EST Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
Nov 03, 2022 4:01pm EDT Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 03, 2022 9:24am EDT Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
Nov 01, 2022 4:01pm EDT Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients
Oct 27, 2022 8:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update
Oct 10, 2022 4:45pm EDT Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
Sep 06, 2022 8:30am EDT Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 02, 2022 4:02pm EDT Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 02, 2022 4:01pm EDT Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
